Background: Parkinson’s disease (PD) is a progressive disorder of the central nervous system. The prevalence of PD varies considerably by age group; it has a higher prevalence in patients aged 60 years and more. Several studies have shown that statin, a cholesterol-lowering medication, reduces the risk of developing PD, but evidence for this is so far inconclusive. The objective of this study is to evaluate the association between statin use and the risk of developing PD. Methods: PubMed, EMBASE, and the bibliographies of articles were searched for studies published between January 1, 1990, and January 1, 2017, which reported on the association between statin use and PD. Articles were included if they (1) were published in English, (2) reported patients treated with statin, and the outcome of interest was PD, (3) provided OR/HR with 95% CI or sufficient information to calculate the 95% CI. All abstracts, full-text articles, and sources were reviewed, with duplicate data excluded. Summary relative risk (RRs) with 95% CI was pooled using a random-effects model. Subgroup and sensitivity analyses were also conducted. Results: We selected 16 out of 529 unique abstracts for full-text review using our selection criteria, and 13 out of these 16 studies, comprising 4,877,059 persons, met all of our inclusion criteria. The overall pooled RR of PD was 0.70 (95% CI 0.58–0.84) with significant heterogeneity between estimates (I2 = 93.41%, p = 0.000) for the random-effects model. In subgroup analysis, the greater decreased risk was found in studies from Asia (RR 0.62 95% CI 0.51–0.76), whereas a moderate reduction was observed in studies from North America (RR 0.69 95% CI 0.47–1.00), but less reduction was observed in studies from Europe (RR 0.86 95% CI 0.80–0.92). Also, long-term statin use, simvastatin, and atorvastatin showed a higher rate of reduction with significance heterogeneity. Conclusion: Our results showed that statin use is significantly associated with a lower risk of developing PD. Physicians should consider statin drug therapy, monitor its outcomes, and empower their patients to improve their knowledge, therapeutic outcomes, and quality of life. However, preventive measures and their associated mechanisms must be further assessed and explored.

Pupillo E, Cricelli C, Mazzoleni F, Cricelli I, Pasqua A, Pecchioli S, Lapi F, Beghi E: Epidemiology of Parkinson’s disease: a population-based study in primary care in Italy. Neuroepidemiology 2016; 47: 38–45.
Hirsch L, Jette N, Frolkis A, Steeves T, Pringsheim T: The incidence of Parkinson’s disease: a systematic review and meta-analysis. Neuroepidemiology 2016; 46: 292–300.
Pringsheim T, Jette N, Frolkis A, Steeves TD: The prevalence of Parkinson's disease: A systematic review and meta-analysis. Mov Dis 2014; 29: 1583–1590.
Paganini-Hill A: Risk factors for Parkinson’s disease: the leisure world cohort study. Neuroepidemiology 2001; 20: 118–124.
Baldi I, Cantagrel A, Lebailly P, Tison F, Dubroca B, Chrysostome V, Dartigues JF, Brochard P: Association between Parkinson’s disease and exposure to pesticides in southwestern France. Neuroepidemiology 2003; 22: 305–310.
Preux P, Condet A, Anglade C, Druet-Cabanac M, Debrock C, Macharia W, Couratier P, Boutros-Toni F, Dumas M: Parkinson’s disease and environmental factors. Neuroepidemiology 2000; 19: 333–337.
Chuang YH, Lill CM, Lee P-C, Hansen J, Lassen CF, Bertram L, Greene N, Sinsheimer JS, Ritz B: Gene-Environment Interaction in Parkinson’s Disease: Coffee, ADORA2A, and CYP1A2. Neuroepidemiology 2016; 47: 192–200.
Becker C, Jick SS, Meier CR: Use of statins and the risk of Parkinson’s disease. Drug Safety 2008; 31: 399–407.
Ritz B, Manthripragada AD, Qian L, Schernhammer E, Wermuth L, Olsen J, Friis S: Statin use and Parkinson’s disease in Denmark. Mov Dis 2010; 25: 1210–1216.
Simon KC, Chen H, Schwarzschild M, Ascherio A: Hypertension, hypercholesterolemia, diabetes, and risk of Parkinson disease. Neurology 2007; 69: 1688–1695.
Henchcliffe C, Beal MF: Mitochondrial biology and oxidative stress in Parkinson’s disease pathogenesis. Nat Rev Neurol 2008; 4: 600.
Danielson SR, Andersen JK: Oxidative and nitrative protein modifications in Parkinson’s disease. Free Rad Biol Med 2008; 44: 1787–1794.
Selley ML: Simvastatin prevents 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine-induced striatal dopamine depletion and protein tyrosine nitration in mice. Brain Res 2005; 1037: 1–6.
Huang X, Chen H, Miller WC, Mailman RB, Woodard JL, Chen PC, Xiang D, Murrow RW, Wang YZ, Poole C: Lower low-density lipoprotein cholesterol levels are associated with parkinson’s disease. Mov Dis 2007; 22: 377–381.
Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D: The -PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med 2009; 6:e1000100.
Higgins JP, Green S (eds): Cochrane Handbook for Systematic Reviews of Interventions. John Wiley & Sons, 2011.
de Lau LM, Stricker BH, Breteler M: Serum cholesterol, use of lipid-lowering drugs, and risk of Parkinson’s disease. Mov Dis 2007; 22: 1985–1985.
Wolozin B, Wang SW, Li NC, Lee A, Lee TA, Kazis LE: Simvastatin is associated with a reduced incidence of dementia and Parkinson’s disease. BMC Med 2007; 5: 20.
Samii A, Carleton BC, Etminan M: Statin use and the risk of Parkinson’s disease: a nested case control study. J Clin Neurosci 2008; 15: 1272–1273.
Gao X, Simon KC, Schwarzschild MA, Ascherio A: Prospective study of statin use and risk of Parkinson disease. Arch Neurol 2012; 69: 380–384.
Friedman B, Lahad A, Dresner Y, Vinker S: Long-term statin use and the risk of Parkinson’s disease. Am J Manag Care 2013; 19: 626–632.
Huang X, Alonso A, Guo X, Umbach DM, Lichtenstein ML, Ballantyne CM, Mailman RB, Mosley TH, Chen H: Statins, plasma cholesterol, and risk of Parkinson,s disease: a prospective study. Mov Dis 2015; 30: 552–559.
Lin KD, Yang CY, Lee MY, Ho SC, Liu CK, Shin SJ: Statin therapy prevents the onset of Parkinson disease in patients with diabetes. Ann Neurol 2016; 80: 532–540.
Hippisley-Cox J, ζ C: Unintended effects of statins in men and women in England and Wales: population based cohort study using the QResearch database. BMJ 2010; 340:c2197.
Lee YC, Lin CH, Wu RM, Lin MS, Lin JW, Chang CH, Lai MS: Discontinuation of statin therapy associates with Parkinson disease a population-based study. Neurology 2013; 81: 410–416.
Wahner AD, Bronstein JM, Bordelon YM, Ritz B: Statin use and the risk of Parkinson disease. Neurology 2008; 70: 1418–1422.
Undela K, Gudala K, Malla S, Bansal D: Statin use and risk of Parkinson’s disease: a meta-analysis of observational studies. J Neurol 2013; 260: 158–165.
Sheng Z, Jia X, Kang M: Statin use and risk of Parkinson’s disease: a meta-analysis. Behav Brain Res 2016; 309: 29–34.
Hunot S, Hirsch E: Neuroinflammatory processes in Parkinson’s disease. Ann Neurol 2003; 53(suppl 3):S49–S58
Kotagal V, Albin RL, Müller ML, Koeppe RA, Frey KA, Bohnen NI: Modifiable cardiovascular risk factors and axial motor impairments in Parkinson disease. Neurology 2014; 82: 1514–1520.
Schernhammer E, Hansen J, Rugbjerg K, Wermuth L, Ritz B: Diabetes and the risk of developing Parkinson’s disease in Denmark. Diabetes Care 2011; 34: 1102–1108.
Huang X, Abbott RD, Petrovitch H, Mailman RB, Ross GW: Low LDL cholesterol and increased risk of Parkinson's disease: prospective results from Honolulu-Asia aging study. Mov Dis 2008; 23: 1013–1018.
Bar-On P, Crews L, Koob AO, Mizuno H, Adame A, Spencer B, Masliah E: Statins reduce neuronal α-synuclein aggregation in in vitro models of Parkinson’s disease. J Neurochem 2008; 105: 1656–1667.
Brakedal B, Haugarvoll K, Tzoulis C: Simvastatin is associated with decreased risk of Parkinson disease. Ann Neurol 2017; 81: 329–330.
Hirtz D, Thurman D, Gwinn-Hardy K, Mohamed M, Chaudhuri A, Zalutsky R: How common are the “common” neurologic disorders? Neurology 2007; 68: 326–337.
Wong SL, Gilmour H, Ramage-Morin PL: Parkinson’s disease: prevalence, diagnosis and impact. Health Rep 2014; 25: 10.
Hu G, Jousilahti P, Bidel S, Antikainen R, Tuomilehto J: Type 2 diabetes and the risk of Parkinson’s disease. Diabetes Care 2007; 30: 842–847.
Sandyk R: The relationship between diabetes mellitus and Parkinson’s disease. Int J Neurosci 1993; 69: 125–130.
Leung HW, Chan AL, Lo D, Leung JH, Chen HL: Common cancer risk and statins: a population-based case-control study in a Chinese population. Exp Opin Drug Safety 2013; 12: 19–27.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.